Agenus is focused in the areas of oncology and infectious diseases. With our strong platform technologies, we have advanced multiple product candidates through the clinic and defined the most suitable patient populations to benefit from our novel vaccine approach. To advance our pioneering work in HSP-based vaccines, we are applying our technology to both autologous and non-autologous therapies. Agenus' licensees for QS-21 Stimulon® adjuvant include GlaxoSmithKline and Janssen Alzheimer Immunotherapy (a wholly owned subsidiary of Johnson & Johnson). QS-21 represents the most advanced adjuvant ...


There are no scholarships at this time


There are no events at this time

Company Data on Agenus
provided by Owler


Agenus is hiring for these positions

Show me: All available jobs